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In Brief
Farshidfar et al. present The Cancer
Genome Atlas (TCGA) marker analysis of
cholangiocarcinoma. Through multi-
platform analyses, they identify a distinct
subtype enriched for IDH mutants. This
subtype shows increased mitochondrial
and decreased chromatin modifier gene
expression, including potential
epigenetic silencing of ARID1A. Other
IDH-mutant liver cancers molecularly
resemble cholangiocarcinoma.
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http://dx.doi.org/10.1016/j.celrep.2017.02.033SUMMARY
Cholangiocarcinoma (CCA) is an aggressive malig-
nancy of the bile ducts, with poor prognosis and
limited treatment options. Here, we describe the
integrated analysis of somatic mutations, RNA
expression, copy number, and DNA methylation
by The Cancer Genome Atlas of a set of predomi-
nantly intrahepatic CCA cases and propose a mo-
lecular classification scheme. We identified an IDH
mutant-enriched subtype with distinct molecular
features including low expression of chromatin
modifiers, elevated expression of mitochondrial
genes, and increased mitochondrial DNA copy
number. Leveraging the multi-platform data, we
observed that ARID1A exhibited DNA hypermethy-2780 Cell Reports 18, 2780–2794, March 14, 2017 ª 2017 The Autho
This is an open access article under the CC BY license (http://creativelation and decreased expression in the IDH mutant
subtype. More broadly, we found that IDH muta-
tions are associated with an expanded histological
spectrum of liver tumors with molecular features
that stratify with CCA. Our studies reveal insights
into the molecular pathogenesis and heterogeneity
of cholangiocarcinoma and provide classification
information of potential therapeutic significance.INTRODUCTION
Cholangiocarcinomas (CCAs) are a group of malignancies of the
biliary epithelium (cholangiocytes), comprising invasive carci-
nomas that arise in the intrahepatic, perihilar, and extrahepatic
biliary tree (Razumilava and Gores, 2014). Most patients with
CCA present with advanced disease and have a median survivalrs.
commons.org/licenses/by/4.0/).
of less than 1 year despite treatment with current standard
chemotherapy (Valle et al., 2010). Even patients who undergo
apparently curative resection have poor outcomes due to a high
rate of tumor recurrence (Razumilava and Gores, 2014). Although
intrahepatic, perihilar, and extrahepatic CCAs share morphologic
features and have traditionally been aggregated in clinical trials, it
is now apparent that there are important differences in tumor
biology and genetics among tumors from different anatomic sites
(Chan-On et al., 2013; Churi et al., 2014). Further elucidation of
molecular alterations in these heterogeneous tumors and discov-
ery of meaningful subtypes within each anatomic group are
important steps toward developing more rational, specific, and
effective treatments (Kelley and Bardeesy, 2015).
Cholangiocarcinoma is the second most common type of pri-
mary liver tumor, and its incidence has been rising in the United
States, from 0.44 per 100,000 in 1973 to 1.18 in 2012 (Saha et al.,
2016). The actual incidence of the disease is likely much higher,
as recent gene expression studies suggest that ‘‘carcinomas-of-
unknown primary’’ identified in the liver most commonly origi-
nate from biliary epithelium (Varadhachary and Raber, 2014).
Worldwide, the highest incidence of CCA is found in north-
eastern Thailand, where parasitic infection by liver flukes (Clo-
norchis sinensis and Opistorchis viverrini) leads to infestation of
the biliary tree (Razumilava and Gores, 2014). In regions without
liver fluke infestation, CCA disease etiologies include: primary
sclerosing cholangitis, hepatitis B or C virus (HBV/HCV) infec-
tion, biliary stone disease, congenital biliary malformations,
cirrhosis, and exposure to aromatic toxins (Razumilava and
Gores, 2014). Lifestyle-related factors such as smoking, alcohol
consumption, and diabetes also contribute to the risk of intrahe-
patic CCA (iCCA) (Palmer and Patel, 2012). Given the diversity of
risk factors influencing the mutational spectrum and the distinct
cellular origins of the CCA subtypes, there is still an incomplete
appreciation of the mechanisms of biliary carcinogenesis.
Prior studies indicate that iCCAs are unusual among epithelial
cancers in having a relatively high rate of missense mutations in
the isocitrate dehydrogenase 1 and 2 (IDH1/IDH2) genes (Borger
et al., 2012; Chan-On et al., 2013; Jiao et al., 2013; Kipp et al.,
2012; Ross et al., 2014; Wang et al., 2013), which encode meta-
bolicenzymes that interconvert isocitrateandalpha-ketoglutarate
in central carbon metabolism. These mutations, which are also
common in acute myeloid leukemia, low-grade glioma and glio-
blastoma, and chondrosarcoma, occur at defined hotspots and
result in neomorphic enzyme activity, leading to production of
high levels of the metabolite (R)-2-hydroxyglutarate (2HG) (Los-
man and Kaelin, 2013). 2HG does not participate in normal meta-
bolic processes but instead interferes with the function of en-
zymes that utilize alpha-ketoglutarate as a co-enzyme, including
histone and DNA demethylases, and inhibits the mitochondrial
electron transport chain (Fu et al., 2015; Parker and Metallo,
2015). Additional recurrent mutations and fusions have been re-
ported in CCAs involving the fibroblast growth factor receptor 2
(FGFR2) gene, as well as in KRAS, BRAF, TP53, and in genes en-
coding chromatin-modifying enzymes (Borad et al., 2014; Churi
et al., 2014; Jiao et al., 2013; Nakamura et al., 2015; Ross et al.,
2014; Sia et al., 2015). Given this complexity, it is imperative to
generate a more integrative model of the molecular alterations in
iCCA to better define the oncogenic circuitry and to derive a clas-sification system that groups tumors into biologically meaningful
subtypes that can be used to guide therapy.
In this study, we describe molecular features of 38 liver fluke-
negative CCAs—predominantly intrahepatic and hepatitis nega-
tive—that stratify the disease into distinct groups. Most notably,
we identify a class of CCAs with distinct transcriptomic, copy
number, and methylation profiles that are highly enriched for
IDHmutant samples. We also identify pathways and methylation
patterns that we validate in external datasets and which could
help lead to the development of more effective treatments.
Finally, cross-platform comparisons of CCAwith pancreatic can-
cer and hepatocellular carcinoma (HCC) further emphasize the
presence of distinct tumor subsets.
RESULTS
Samples
We analyzed 38 CCA samples that were predominantly from
North America (89%), intrahepatic (84%), fluke-negative (100%),
and HBV/HCV-negative (97%, as assessed by combined DNA
and RNA sequencing, which also revealed no HBV integration
sites), and had no prior exposure to chemotherapy or radiation
(Tables 1 and S1). This relative overall sample uniformity mini-
mizes known and potential sources of molecular heterogeneity
in our sample set.
The TCGA analysis pipeline used in this study consists of the
following platforms: whole-exome sequencing; Affymetrix SNP
6.0 copy number array; RNA sequencing (RNA-seq), including
microRNA (miRNA) and long noncoding RNA (lncRNA); DNA
methylation; and reverse-phase protein array (RPPA) utilizing
192 antibodies. These datasets are annotated with relevant clin-
ical information and careful histopathologic review by several
experienced hepatobiliary pathologists (Table S1).
Gene-Level Mutations, Fusions, and Copy Number
Alterations
We first annotated alterations to specific genes. Whole-exome
sequencing identified 2,831 somatic mutations, of which 1,869
(66%) were non-silent coding mutations. Targeted-capture,
deep sequencing validation of 43 selected genes confirmed 77
mutations and newly identified nine (see Supplemental Experi-
mental Procedures and Table S2). The median mutation rate
was 1.38 per megabase, with a median mutation count of 49 (Fig-
ure 1A; Table S1). Compared to other cancers assessed by TCGA
(Lawrenceetal., 2013), thisCCAmutation rate is intermediate, and
comparable to that of pancreatic ductal adenocarcinoma (PDAC).
Consistent with previous studies, we identified inactivating
mutations in the tumor suppressor genes ARID1A, ARID1B,
BAP1, PBRM1, TP53, STK11, and PTEN, and hotspot gain-of-
function mutations in the oncogenes IDH1, IDH2, KRAS,
BRAF, and PIK3CA (Figures 1A and S1A; Tables S1 and S3).
Also consistent with prior reports, the IDH mutant alleles
described in our cohort (IDH1R132C and IDH2R172K/S) are distinct
from those found in glioma and acute myeloid leukemia (en-
riched for IDH1R132H and IDH2R140Q) (Cancer Genome Atlas
Research Network, 2013; Brat et al., 2015). In two tumors, we
identified a recurrent P216L mutation in the regulatory domain
of ARAF adjacent to the functionally validated N217I mutationCell Reports 18, 2780–2794, March 14, 2017 2781
Table 1. Patient Characteristics
Characteristics Number of Patients
Total number of patients 38
Median age at diagnosis (years) 66 (range 29–82)
Gender
Female 21
Male 17
ECOG PS
0 19
1 9
2 0
3 1
Unknown 9
Histologic Grade
G1 5
G2 21
G3 9
G4 2
Unknown 1
Resection status (R0/R1/Rx) 28/7/3
Tumor Stage
T1 19
T2 (T2a/T2b) 15 (2/5)
T3 4
Histologic Diagnosis
Intrahepatic 32
Extrahepatic/hilar 4
Mixed ICC/HCC 2
Lymph node status (N0/N1/Nx) 26/5/7
Metastatic disease (M0/M1/Mx) 30/4/4
Lymphovascular invasion (yes/no/
unknown)
15/22/1
Perineural invasion (yes/no/unknown) 4/33/1
Elevated CA 19-9 (yes/no/unknown) 18/13/7
Race (white/Asian/black) 33/3/2
Country submitting tumor (USA/Canada/
Italy/Brazil/Vietnam
30/4/2/1/1
Elevated CA 19-9 (yes/no/unknown) 18/13/7
Presence of fluke infection (Y/N) 0/38
ECOG, Eastern Cooperative Oncology Group.(Sia et al., 2015), which suggests an activated state. We also
identified two frameshift deletions and one missense mutation
S217F (Zou et al., 2014) in the albumin gene (ALB), one of the
most significantly mutated genes in HCC (Schulze et al., 2015).
Finally, we detected a single telomerase reverse transcriptase
(TERT) promoter mutation, in a mixed HCC/iCCA sample. To
further validate the observed mutations, we performed whole-
exome sequencing and targeted deep validation on an indepen-
dent set of 15 samples (Figure 1B). Although analyzed sepa-
rately, these additional samples corroborated the mutations
above and highlighted additional recurrent mutations in the
BRCA2, MLL3, APC, NF1, and ELF3 tumor-suppressor genes.2782 Cell Reports 18, 2780–2794, March 14, 2017An analysis of gene fusions from RNA-seq data identified five
samples (13%) that expressed FGFR2 fusion transcripts; this
prevalence is consistent with other studies (Arai et al., 2014;
Churi et al., 2014; Goyal et al., 2016; Nakamura et al., 2015;
Ross et al., 2014). Our cases included two with the known fusion
partner BICC1 and three with the partners KIAA1598, FRK, and
C10ORF118 (Table S3). Other than the FGFR2-FRK fusion,
which resulted in loss of the FGFR2 kinase domain and retention
of the FRK kinase domain, the rest of the fusions retained the
kinase domain, consisting of FGFR2 exons 1–17 spliced in
frame with the partner gene. We note that BICC1, KIAA1598,
and C10ORF118 are located on chromosome 10 along with
FGFR2. We also observed two missense mutations and one in-
frame insertion in FGFR2.
Somatic copy number alterations (SCNAs) determined by
analysis of high-density SNP data identified recurrent focal
losses of CDKN2A and amplifications of CCND1. We further
identified low-prevalence cases of focal SCNAs that have been
reported in other cancers, including amplification of CDK4/
MDM2 and homozygous focal deletion of QKI and SAV1 (Table
S1; Figure S1B). The functional perturbation of these genes is
supported by correlative gene expression data (Figure S1C).
Epigenetic silencing of CDKN2A was identified in eight cases
(21%) and was mutually exclusive with homozygous deletions
and mutations (Figures 1, S1D, and S1E). Collectively, CDKN2A
was mutated, deleted, or silenced in 47% of cancers, a higher
rate than previously appreciated with single platform analyses.
Next, cross-comparing sequencing and copy number data,
we found that all mutations in BAP1 and PBRM1 (both located
on 3p21) were detected in tumors with 3p loss of heterozygosity,
suggesting biallelic inactivation of these genes in near-diploid tu-
mors. Cancer cell fractions were higher for the broad or arm-level
loss of chromosome 3 than for BAP1 mutations, followed by
PBRM1 mutations, suggesting that these events occur chrono-
logically (3p loss, BAP1, PBRM1) in CCA development (Figures
S1F and S1G). We also note that the NF2 splice site mutation
in sample AA0S experienced loss of heterozygosity, suggesting
bi-allelic loss of this Hippo pathway tumor suppressor gene.
Finally, using a previously defined mutational signature
assessment (Covington et al., 2016) and non-negative matrix
factorization, we identified seven enriched mutation signatures
out of 21 total signatures. As observed across 31 tumor types
analyzed to date (Covington et al., 2016), the most common
signature was C > T/G > A substitutions at CpG islands (signa-
ture #6), followed by signature #1, characterized by AC > AN,
AT > AN (Figure 1).
Filtering Normal Liver Genes Uncovers an IDH-Mutant-
Enriched mRNA Subgroup
We next analyzed mRNA expression by unsupervised hierarchi-
cal clustering, selecting only the most variable 2% (i.e., 400) of
genes. The two resultant clusters showed a large differential
expression of the genes (Figure S2A) with strong enrichment
for a liver-associated signature. However, the clusters did not
correlate with any other molecular or clinical parameter. Given
that most liver signature genes are expressed in normal liver at
levels 1,000- to 20,000-fold higher than in tumors, we considered
that the liver signature expression in part reflected contamination
Figure 1. Somatic Alterations in Cholangiocarcinoma
(A and B) Significantly mutated genes identified using the MutSigCV algorithm, and additional genes with chromosomal alterations, hotspot mutations (red font),
and possibly functional mutations, grouped by pathway. (A) TCGA analysis sample set (n = 38). (B) Additional sample set (n = 15). Left, mutation amount and
percentage, plus epigenetic silencing for CDKN2A. Top, overall number of mutations per megabase. Bottom, mutation spectra signatures. Dashed yellow line in
upper panel indicates median mutations/megabase.by even a small amount of normal liver. Consistent with this
hypothesis, histological analysis revealed a trend toward higher
normal liver contamination in the liver-high cluster (Figure S2C),
which was not picked up by DNA-based tumor purity esti-
mates. This indicates that high-expressing stromal genes likely
confound mRNA expression clustering, particularly when using
only the top-most variable genes.
To reduce the statistical effects of the liver signature, 386 liver-
specific genes derived from the GTEx (Genotype-Tissue Expres-
sion) normal tissue expression database (Lonsdale et al., 2013)
(Table S4) were filtered out. The remaining 15,427 genes under-
went principal component analysis (PCA) (Figures 2A and 2B),
identifying three clusters. A subset of 1,150 genes was identifiedby orthogonal partial least-squares discriminant analysis (OPLS-
DA) as most strongly contributing to cluster separation (Fig-
ure 2A). Intriguingly, cluster 1 included all seven cases with an
IDH1 or IDH2 hotspot mutation, while cluster 2 was enriched in
extrahepatic or perihilar CCA, and cluster 3 contained all five
FGFR2 fusions. This was validated by comparison with the previ-
ously generated microarray gene expression dataset GSE26566
(Andersen et al., 2012; Wang et al., 2013). Hierarchical clustering
was performed for the 976 most strongly discriminant genes
shared between datasets (Figure 2C). In this validation cohort
of 40 samples, threemain clusters were identified that resembled
the TCGA dataset clusters. Notably, most IDH1/2 mutations
(eight of ten) were located in the cluster that most stronglyCell Reports 18, 2780–2794, March 14, 2017 2783
Figure 2. mRNA Analysis of Cholangiocarcinoma Identified an IDH-Enriched Cluster
(A and B) Principal component analysis of RNA-seq expression data of 15,272 genes after exclusion of 541 normal liver genes. The heatmap in (A) shows themost
strongly discriminant 973 genes (shared between the TCGA and the GSE26566 dataset) that define the three clusters. (B) Three-dimensional PCA plot of TCGA
CCA samples.
(C) Hierarchical clustering analysis of 40 samples from the CCAmicroarray dataset GSE26566, using the same 973 genes as in (A). Genes in heatmaps (A) and (C)
are shown in the same order.resembled the IDH-mutant-enriched TCGA cluster 1. Thus,
removal of the liver signature unmasked transcriptional clusters
that segregated samples in a biologically relevant manner.
The IDHMutant Subgroup Is Enriched for Mitochondrial
and Chromatin-Modifier Signatures
We next performed gene set enrichment analysis (GSEA) on the
mRNA clusters and discovered an enriched expression of genes
involved in mitochondrial structure and function in the IDH-2784 Cell Reports 18, 2780–2794, March 14, 2017mutant-enriched cluster 1. This included notable upregulation
of genes encoding citric acid cycle enzymes, mitochondrial ribo-
somal proteins, electron transport chain components, and mito-
chondrial structural constituents, consistent with altered control
of oxidative phosphorylation and mitochondrial biogenesis (Fig-
ure 3A; Tables S5 and S6) (hereafter collectively referred to as
‘‘mitochondrial gene expression’’). High mitochondrial gene
expression was significantly associated with IDH and PBRM1
mutant samples and low expression with FGFR2-fusion samples
(legend on next page)
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(Figure 3B and depicted as a condensed ‘‘mitochondrial score’’
in Figure 3D); these correlations were improved by removing
low-purity (<0.65) samples, a possible confounding factor (Fig-
ures S3A and S3B). In keeping with potential functional
relevance of the differential expression of mitochondrial genes,
we identified a relatively higher mitochondrial copy number
(Reznik et al., 2016) in IDH mutant samples and a lower number
in FGFR2-fusion samples (Figure 3E).
Examination of the GSE26566 dataset (Andersen et al., 2012)
provided an external validation of these findings, again identi-
fying an enrichment of IDH mutants among the tumors with
high expression of the mitochondrial gene signature (Figure 3C).
This association between this signature and IDH mutations
appears to be particular to CCA, since it was not observed
upon analysis of TCGA datasets for glioblastoma, low-grade
glioma, melanoma, or acute myeloid leukemia TCGA datasets
(Figure S3C).
GSEA also identified chromatin modifier gene sets as signifi-
cantly downregulated in the IDHmutantmRNAcluster (Figure 3A;
Tables S5, S6, and S7. Notably, these included genes recurrently
mutated in CCA—ARID1A, ARID1B, and PBRM—as well as
genes whose protein products are known to be inhibited by
IDH-mutant-generated 2HG, including TET2, TET3, KDM2A,
and KDM5B (Xu et al., 2011). Expression of the chromatin
modifier geneset anticorrelated with the mitochondrial geneset
even when considered as a gradient (Figure S3D; Table S7).
Querying of this association in multiple TCGA gene expression
datasets demonstrated strikingly consistent anticorrelation of
these two pathways across 23 of 25 cancer types (Figure 3F)
as well as across and within normal tissues (Figure S3E) from
the GTEx database for most genes. These results suggest that
mitochondrial activity and chromatin modification are linked
basic biological events that are also regulated by IDH hotspot
mutations in CCA.
Cluster-of-Clusters Analysis Identifies Four Subgroups
We next enlisted the additional platforms (copy number, methyl-
ation, miRNA, lncRNA, and protein) into a clustering of the cluster
assignments (COCAs) (Hoadley et al., 2014), which provides a
way to distinguish sample subtypes by identifying patterns
across platforms. We started by performing hierarchical clus-
tering of each platform separately. First, copy number based
on SNP array hybridization data (Figure 4A) revealed four
genomic clusters. We note that this clustering is performed on
select SCNAs determined by genome identification of significantFigure 3. IDHMutant Cancers Are Enriched for a High Mitochondrial Sig
Signature
(A) GSEA analysis identified mitochondrial and chromatin modifier genes as sign
Selected pathways are shown, omitting genesets that show a high degree of gene
Table S6. NES, normalized enrichment score; size, geneset size.
(B and C) Heatmaps of the most significant mitochondrial and chromatin-modifi
purity (>0.65); unfiltered results are shown in Figure S9.
(D and E) Quantification of mitochondrial signature (D) andmitochondrial DNA (E) c
subgroup by itself is significantly different from all other samples, indicating only
whisker plots show maximum and minimum bars.
(F) Pan-cancer correlation analysis of mitochondrial and chromatin modifier genes
order. Red signifies high positive Spearman correlation values; green denotes hig
mitochondrial genes. Genes are listed in Table S8.
2786 Cell Reports 18, 2780–2794, March 14, 2017targets in cancer (GISTIC) analysis to be significantly differen-
tially altered, as using all data points results in overfitting. This
approach therefore highlights samples that share loci that are
likely undergoing positive selection in the tumor. Cluster 4
consisted entirely of tumors with high-level amplification of
CCND1. Cluster 2 was characterized by enrichment of chromo-
somal deletions, particularly 6q, 9, and 14. Cluster 3 tumors con-
tained mostly SCNAs that were found across the larger set of
tumors (e.g., 1p loss and 1q gain), but on average had fewer
arm-level deletions than cluster 2. Last, cluster 1 consisted of
molecularly atypical tumors, including two genomically silent
cases that were completely devoid of copy number alterations
or recurrent CCA driver mutations (the low-purity extrahepatic
W5-AAH2 and the 0.61-purity intrahepatic ZH-A8Y6).
Next, unsupervised clustering of samples using CpG sites that
show cancer-specific DNA methylation changes identified four
subgroups in our CCA cohort (Figure 4B). Tumors in cluster 1
showed minimal alterations in DNA methylation compared with
normal liver, which is at least partially explained by low tumor
purity for most of the samples. The remaining tumors had
prominent DNA hypermethylation and were classified into three
subgroups. All seven IDHmutant tumors were present in cluster
4, along with one IDH-wild-type case that exhibited a gene
expression profile similar to that of IDHmutants (see Figure S4A).
Surprisingly, on average, tumors in cluster 2 showed an even
greater degree of DNA hypermethylation than did IDH mutant
tumors (Figures 4B and S4B). Last, we note that tumors in clus-
ters 2 and 3 had frequent mutation of genes encoding chromatin
regulators, including PBRM1 and ARID1A (ten of 20).
We observed that the copy number and methylation clusters
generally matched the mRNA clusters identified in Figure 3, sug-
gesting the ability of the data to detect shared biological mech-
anisms. By contrast, hierarchical clustering of mature miRNAs,
lncRNAs, and protein yielded clusters that were discordant
with the other platforms. We believe this is mainly due to the
far smaller number of informative features available for clustering
(169, 101, and 192, respectively) given the sample size (Fig-
ure S4). As expected, COCA analysis using all six platforms
gave a discordant pattern with no clinical correlates, even
when the lower-sample number RPPA was removed. We there-
fore conducted the COCA analysis using only mRNA, copy
number, and methylation to discern biologically coherent clus-
ters. We optimized a four-cluster solution (see Experimental
Procedures) that was not dominated by any one platform
(Figure 4C).nature andMitochondrial DNA Count and a LowChromatin Modifier
ificantly differentially expressed in the IDH-mutant-enriched mRNA cluster 1.
membership overlap with the displayed pathways. Full results are available in
er genes for TCGA (B) and GSE26566 (C). TCGA samples are filtered for high
ount for different mutational subgroups, showing high-purity samples only. No
enrichments and not exclusivity for high/low mitochondrial markers. Box and
. For each cancer, the genes on the x and y axes are the same and in the same
h negative values for each gene-gene comparison. C, chromatin modifiers; M,
(legend on next page)
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We then correlated clinical data and molecular aberrations
with the four COCA clusters (Figure 4C; Table S1). IDH hotspot
mutations were present exclusively in COCA2 (p = 0.0004;
‘‘IDH COCA’’), reflecting the mRNA and methylation specificity
noted earlier, and identifying a correlation with copy number
cluster 2 (‘‘genomically unstable’’). Patients with IDH COCA tu-
mors were typically nonsmokers, and the tumors exhibited a
lower frequency of lymphatic invasion and chromosome arm
8p gains (Figure 4C). Three of four distal or hilar tumors were in
COCA1 (p = 0.003; ‘‘ECC COCA’’), which exhibited the following
characteristics: wild-type for FGFR2, IDH1/2, ARID1A, BAP1,
and PBRM1; low methylation; and relative genomic silence for
copy number alterations. COCA3 was enriched for samples
with CCND1 amplification and with the most highly hypermethy-
lated profile (methylation cluster 2; ‘‘METH2 COCA’’). COCA4
(‘‘METH3 COCA’’ contained eight of 12 cases with BAP1 muta-
tions (p = 0.01) and all five FGFR2 fusion cases (p = 0.004). Sur-
vival analysis among the COCA clusters did not yield significant
p values, possibly due to the small sample size. All clustering
solutions for individual platforms and for COCAs, as well as
key genetic, clinical, and pathologic data are available in Table
S1. We posit that these COCAs identify biologically distinct
CCA subtypes with potential clinical implications; however, we
also acknowledge the limitations due to the sample number,
and that validation of these subtypes awaits new comparable
datasets and functional confirmation in model systems. Never-
theless, these results clearly highlight the molecular distinctness
of IDH mutants and the power of integrated multiplatform
analyses.
ARID1A Promoter Hypermethylation and Decreased
Expression in IDH Mutants
To extend our analysis of the IDH mutant subgroup, we
considered that the COCA classifications may help reveal new
cross-platform insights. To this end, we asked whether IDH-
mutant-specific DNA hypermethylation may target genes that
show decreased expression in the IDH COCA subtype. We
restricted the analysis to high-purity samples to avoid assessing
gene expression changes that are primarily associated with
contaminating stroma rather than with methylation. After inter-
secting IDH mutant hypermethylated loci with genes with
decreased expression in the IDH COCA subtype and filtering
for gene-specific anticorrelation between the two platforms,
we identified a list of 24 genes whose expression is putatively
regulated by IDH mutant hypermethylation (Figures 5A and
5B). To validate this list, we cross-referenced it with the matched
CCA methylation and expression datasets GSE32079 and
GSE26566, respectively (Andersen et al., 2012; Wang et al.,
2013). GSE32079 uses the same methylation array platform as
the TCGA dataset, allowing for direct comparison of probes.Figure 4. Cluster-of-Clusters Analysis of CCAs
(A) Unsupervised hierarchical clustering of copy number data. The clustering is p
altered, as shown in the lower heatmap.
(B) Unsupervised hierarchical clustering of DNA methylation data.
(C) The cluster-of-clusters analysis (COCA) was performed on the three platform
ation). Bottom, robustness scores indicating strength of cluster membership ass
clustering, genetic, clinical, and pathological data are available in Table S1.
2788 Cell Reports 18, 2780–2794, March 14, 2017While all 24 genes once again showed IDH-mutant-specific
hypermethylation (Figure 5C), only three genes, ARID1A,
MARVELD1, and SLC1A5 were significantly downregulated (Fig-
ure 5D) in the ‘‘IDH-like’’ mRNA cluster (cf. Figure 2C). Given the
bona fide tumor suppressor role of ARID1A in the liver, we
explored the relationship between DNAmethylation and expres-
sion further (Figure 5E). Of four IDH-wt samples in the IDHCOCA,
two were ARID1A mutant with low ARID1A expression. More-
over, the only IDHmutant to not showARID1A hypermethylation,
A95A, was ARID1A mutant with low expression (Figures 5A and
5E), suggesting that ARID1A mutation and IDH-induced hyper-
methylation are mutually exclusive due to redundancy. Analysis
of publically available histone modification ChIP-seq data
showed that the two hypermethylated ARID1A probes were
located in the ARID1A promoter within the active transcription
marks H3K27Ac and H3K4me3 (Figure 5F). Collectively, these
data suggest that IDH mutations result in hypermethylation and
silencing of ARID1A, and that impingement of ARID1A is a
convergent feature of IDH COCA tumors.
lncRNAs Associated with the Chromatin Modifier
Signature
Given the centrality of the chromatin modifier signature to the
IDH COCA subtype, we explored the remaining platforms to
identify non-mRNA members of the signature. As lncRNAs are
relatively understudied, we sought to identify lncRNAs that
correlated with the mRNA-based chromatin modifier signature.
To further limit the resulting set of 66 lncRNAs, we asked which
ones also tracked with the chromatin modifier signature across
other TCGA datasets (cf. Figure 3F). Across eight assessed
cancers, we found that 21 of the lncRNAs correlated with the
chromatin modifier signature in at least six cancers (Figure S5A;
Table S7). Importantly, only an estimated eight of the 66 lncRNAs
were expected to correlate by chance, making 21 a significant
enrichment (p = 0.01, Fisher’s exact test). These findings
suggest potential functions for these 21 lncRNAs, which have
not previously been studied.
Additionally, we identified lncRNA clusters that correlate with
immune and liver mRNA signatures (Figures S5B and S5C) in
the CCA dataset. To validate these, we determined the overlap
with high-stringency immune- and liver-specific lncRNAs
defined from the GTEx database (Lonsdale et al., 2013): for
immune-associated lncRNAs, 34/48 CCA-derived lncRNAs
overlapped with 190 GTEx lncRNAs (p = 2 3 1013), while for
liver-associated lncRNAs, 25/25 CCA-derived lncRNAs overlap-
ped with 127 GTEx lncRNAs (p = 43 1013). These clusters lend
support to the biological fidelity and analytical utility of the
lncRNA platform and provide starting lncRNA candidates when
analyzing future samples. For miRNAs, we note that miRNA-
194-5p is significantly upregulated in the IDH COCA subtypeerformed on SCNAs that are determined by GISTIC analysis to be significantly
s with the strongest degree of correlation (mRNA, copy number, and methyl-
ignment for each sample. Selected information of interest is shown here; full
Figure 5. ARID1A Is Hypermethylated and Has Low Expression in the IDH COCA
(A and B) TCGA methylation (A) and RNA-seq (B) data for 24 genes (36 probes) that show both IDHmut-specific hypermethylation and downregulation in the IDH
COCA subtype.
(C and D) Methylation (C) and microarray (D) data for the same 24 genes and 36 methylation probes as in (A and B), in the publically available datasets GEO:
GSE32079 and GSE26566.
(E) Scatterplot of TCGA methylation and RNA expression values for ARID1A.
(F) Location of the two ARID1A hypermethylated probes within the ARID1A promoter. ENCODE histone marks for H3K27Ac and H3K4me3 are shown.and negatively correlated with the chromatin modifier signature
(Figures 4 and S5D–S5H). Notably, miRNA-194 has been impli-
cated as a suppressor of invasion in liver cancer in vitro (Meng
et al., 2010). The results of these analyses collectively demon-
strate the robustness of the pan-cancer and cross-platform
capacity of the TCGA.Comparison with HCC and PDAC
Wenext compared liver, pancreatic, and biliary cancer across the
standardizedmultiplatformTCGAdatasets to determine theirmo-
lecular relationships (Boradet al., 2014). First, to improve compar-
isons ofmutational landscapes, we conducted ameta-analysis of
six iCCA sequencing studies (Churi et al., 2014; Jiao et al., 2013;Cell Reports 18, 2780–2794, March 14, 2017 2789
Nakamura et al., 2015; Ruzzenente et al., 2016; Zou et al., 2014)
including this one, totaling 458 samples (Table S8). Whereas
PDAC is dominated by KRAS (92%) and TP53 (70%) mutations,
KRAS/NRAS and TP53 mutations comprise only 20% and 21%
of iCCAs, respectively. HCC is characterized by TERT promoter
(46%) andCTNNB1 (26%)mutations, neither of which are present
in iCCA; otherwise HCC shares only three genes with iCCA that
are mutated at >5% (TP53, BAP1, and ARID1A).
We next applied the Tumor Map algorithm, which generates
‘‘islands’’ of cancers based on similarity within chosen platforms
(Davis et al., 2014). IncorporatingmRNA expression, copy number,
and methylation data (Figure 6A), this analysis separated most
HCC, PDAC, and CCA samples into their respective cancer-type
islands; however, sevenof 38 (18%)CCAsampleswereembedded
in thePDACandHCC islands, and sevenof 179 (4%)HCCsamples
were embedded in the CCA island, suggesting that some samples
have discordant histopathologic and molecular profiles.
To better understand these discordances, we illustrated clus-
ter memberships for all 292 CCA/HCC/PDAC samples (Table S9)
after clustering within each molecular platform (mRNA, miRNA,
RPPA, copy number, and methylation; Figures S6A–S6F). First,
we noted that most of our COCA1 CCA samples (distal/hilar
CCA-enriched) clustered with PDAC, consistent with the related
developmental origins of the extrahepatic and pancreatic ducts
from the foregut endoderm. Second, we studied in greater depth
the seven HCCs that mapped with CCA. These tumors shared
several molecular features with CCA, including mRNA and
miRNA expression patterns, DNA methylation, and to a lesser
extent copy number (Figure 6B). Moreover, they lacked TERT
promoter mutations, which are a hallmark of HCC but are absent
in CCA. Strikingly, five of those seven samples harbored either
hotspot IDH1/2 mutations (n = 4) or an FGFR2 fusion (n = 1),
and they were the only cases in the HCC dataset with these mu-
tations. Re-examination of their histology revealed that although
regions of these seven cases fall within the spectrum of HCC,
each of the five tumors with IDH1 or FGFR2 lesions had some
features that have also been described in iCCA, including focal
to diffuse glandular differentiation, abundant fibrotic stroma
(desmoplasia), and in some areas, an anastomosing architecture
(Figures S6G–S6L) (Bledsoe et al., 2015; Liau et al., 2014; Naka-
numa et al., 2012). Consistent with this, these samples ex-
pressed bile duct (e.g., SOX9) and hepatocellular (e.g., HNF4A,
HNF1A) markers at levels within that of iCCA (Figures 6C, S6M,
and S6N). Analysis of the 600 genes that are most enriched in
these tumors compared with standard HCC corroborated this
close transcriptional similarity to CCA (Figure 6C). These data
are notable in view of accumulating evidence that CCA and
HCC lie along a spectrum of primary liver carcinomas, with inter-
mediate subsets exhibiting overlapping phenotypes. The prom-
inent enrichment of IDHmutations in molecularly CCA-like HCCs
is consistent with previous findings that IDHmutations block liver
progenitor cells from undergoing hepatocyte differentiation and
shift them toward a cholangiocellular fate (Saha et al., 2014).
DISCUSSION
Taking advantage of the molecular resolution provided by
multiple genomic platforms, we identified distinct mRNA, DNA2790 Cell Reports 18, 2780–2794, March 14, 2017methylation, and copy number subgroups that together specify
biologically relevant CCA classes. In particular, we highlight an
IDH-mutant-enriched class whose samples share similar profiles
across these three platforms. Notably, this class exhibits high
expression of mitochondrial genes, including components of
the citric acid cycle and electron transport chain, accompanied
by relatively high mitochondrial DNA copy number, as well as
low expression of chromatin modifier genes. This anticorrelation
of mitochondrial and chromatin modifier signatures appears to
be a basic biological link spanning nearly all TCGA cancers
and normal GTEx tissues analyzed (Figures 2F and S9), warrant-
ing deeper mechanistic studies. The anticorrelation is consistent
with the hypothesis that global changes in histone acetylation
and DNA methylation rates affect mitochondrial metabolism via
imbalances in available pools of acetyl and methyl moieties
(Martinez-Pastor et al., 2013). Relevantly, IDHmutants hyperme-
thylate and putatively silence the ARID1A promoter, which
may contribute to the lowered chromatin modifier signature
expression.
Moreover, we identify a group of liver tumors with an atypical
histopathology and a highly CCA-like molecular profile that is en-
riched for IDHmutations, consistent with the emerging view that
liver tumors comprise a continuous spectrum (Fan et al., 2012;
Holczbauer et al., 2013; Marquardt et al., 2015; Sekiya and Su-
zuki, 2012). Given the molecular and partial histologic similarity
to CCA, this potential subtype may be a distinct clinical entity
and strongly warrants further study into its most beneficial clas-
sification. Furthermore, the complete lack of IDH mutations in
otherwise standard HCC from the TCGA set (0/172) has implica-
tions about specific functions of mutant IDH in modulating liver
cell identity and also underscores the benefit of combined
molecular and histopathological diagnosis. Although previous
studies also identified transcriptionally CCA-like HCC (Oishi
et al., 2012; Seok et al., 2012; Woo et al., 2010), our results iden-
tify IDH and FGFR2 perturbations as associated drivers linked to
methylation, miRNA, and copy number similarities. Together,
these findings highlight the uniqueness of IDH-mutant-driven
cancers and the importance of defective chromatin regulation
in the pathogenesis of CCA.
Improved molecular classification of cholangiocarcinoma is
urgently needed, as heterogeneity presents a serious challenge
to clinical management. Unlike cancers in which a few predom-
inant oncogenic loci converge on a pathway, such as KRAS in
PDAC or the mostly mutually exclusive BRAF, NRAS, and NF1
in melanoma, CCA is marked by a heterogeneous set of often-
overlapping, lower-penetrance driver genes across diverse
signaling pathways. This intertumoral heterogeneity is further
exacerbated by geographically distinct molecular profiles and
is modified by the presence or absence of liver fluke infestation
and/or viral hepatitis, and by the anatomic location of the cancer.
As examples, (1) extrahepatic CCAs have more SMAD4 muta-
tions than iCCAs (Churi et al., 2014; Ong et al., 2012); (2) a Chi-
nese study found a much lower incidence of IDH (5%), PBRM1
(1%), and BAP1 (1%) mutations (Zou et al., 2014) in iCCAs;
and (3) liver fluke- and/or viral hepatitis-positive cancers have a
higher incidence of TP53 mutations and lower incidence of IDH
mutations (Chan-On et al., 2013; Ong et al., 2012; Zou et al.,
2014). In this study, we focused on intrahepatic and fluke- and
Figure 6. Cross-Cancer Analysis Comparing TCGA Cholangiocarcinoma, HCC, and Pancreatic Adenocarcinoma
(A) Tumor map analysis incorporating mRNA, methylation, and copy number showing proximity of each sample.
(B) COCA across miRNA, copy number, DNAmethylation, RPPA, and TumorMap for the three cancer types. Unsupervised clustering was performed within each
data type across a cohort of 292 samples from CCA, HCC, and PDAC to derive cross-tumor subtypes (miRNA n = 4; copy number (CN) n = 5; DNA methylation
(DNAmeth) n = 7; RPPA n = 6; tumor map n = 7; see Figure S6 for individual platform cluster solutions). Individual classification subtypes were then used as input
for pan-tumor COCA analysis identifying three COCA classes (first bar; K1, light green; K2, dark blue; K3, light blue). Second annotation bar denotes histology
type – CCA, HCCC, PDAC. Third bar indicates the CCA-specific subtype classification (ECC, METH2, Meth3, and IDH, cf. Figure 5). Fourth bar notes IDH1
mutation status (red, R172 mutations; blue, R132 mutations; black, other mutations). Fifth bar indicates samples with FGFR2 fusions. Sixth bar indicates CCA
score, a median value of the 600most-enriched genes in CCA (see C). The bottom heatmap indicates sample membership for each of the individual classification
subtypes (black, subtype member; white, not a subtype member; gray, missing data). Each row is labeled by platform and subtype number.
(C) Six hundred genes enriched in cholangiocarcinoma-like HCC.hepatitis-negative CCA, which minimized heterogeneity and
improved the ability to apply categorizing statistics. Although
larger studies are needed to validate and identify further molec-
ular subclasses, our results provide a proof of principle thatsubclasses of CCAs have distinct multi-level molecular charac-
teristics that suggest potential therapeutic approaches.
In this regard, the enriched mitochondrial gene signature and
coordinate increase in mitochondrial number in IDH mutantCell Reports 18, 2780–2794, March 14, 2017 2791
CCA is intriguing in light of prior work implicating mutant IDH in
the impairment of multiple aspects of cell metabolism (Cuya`s
et al., 2015; Grassian et al., 2014; Tateishi et al., 2015). These
observations include 2HG-mediated disruption of components
of the mitochondrial electron transport chain, and inhibition of
reductive glutamine metabolism, a wild-type IDH1-dependent
process that is important for fatty acid synthesis in cells with
dysfunctional mitochondria (Fu et al., 2015; Grassian et al.,
2014; Leonardi et al., 2012). The IDH mutant iCCA profile might
thus reflect an adaptive response to mitochondrial dysfunction
and/or an increased reliance on mitochondrial activity for tumor
growth. The decrease in expression of chromatin regulators is
also notable given the potential widespread effects of 2HG on
epigenetic states via inhibition of TET family cytosine oxy-
genases and Jumonji domain family histone demethylases (Xu
et al., 2011). However, the significance of this signature is difficult
to interpret, since the genes contributing to the signature
spanned all classes of chromatin regulators as well as 21 newly
associated lncRNAs. Nevertheless, the discovery of distinct mo-
lecular features of IDHmutant iCCA is noteworthy in light of early
clinical data using IDH1-mutant-specific inhibitor (Burris et al.,
2015). While promising, these data suggest that single-agent
treatment with these drugs may not be sufficient to produce
durable responses or remissions. Thus, targeting aspects of
metabolism (e.g., using inhibitors of oxidative phosphorylation)
or of chromatin regulation are tentatively suggested by our
genomic findings as avenues for future research. Notably, prior
work has suggested that BAP1, PBRM1, and ARID1A deficiency
all result in sensitivity to EZH2 inhibition across cancer types
(Kim et al., 2015; LaFave et al., 2015); the association of ARID1A
methylation with IDH mutation opens the question of whether
EZH2 inhibition might also be effective in this subtype. Collec-
tively, our findings reveal distinct molecular characteristics of
IDH mutant cholangiocarcinoma, offering insights and valuable
multi-omics data as a springboard for future basic and transla-
tional research into this deadly disease.
EXPERIMENTAL PROCEDURES
Cholangiocarcinoma (CCA) tumors were collected and shipped to a central
Biospecimen Core Resource (BCR) between August 15, 2013 and January
20, 2014. Qualifying tumor samples were obtained from patients who had
received no prior chemotherapy or radiotherapy treatment for their disease.
Specimens were shipped overnight from 12 Tissue Source Sites (TSSs) using
a cryoport that maintained an average temperature of less than180C. TSSs
contributing biospecimens included Barretos Cancer Hospital (Barretos,
Brazil); Emory University (Atlanta, GA, USA); Garvan Institute of Medical
Research (Darlinghurst, NSW, Australia); ILSbio, LLC (Chestertown, MD,
USA); Mayo Clinic (Rochester, MN, USA); Sapienza University of Rome
(Rome, Italy); Spectrum Health (Grand Rapids, MI, USA); University of Calgary
Alberta Health Services (Calgary, AB, Canada); University of California - San
Francisco (San Francisco, CA, USA); University of New Mexico (Albuquerque,
NM, USA); University of North Carolina (Chapel Hill, NC, USA); Wake Forest
University (Winston-Salem, NC, USA).
In addition to tumor samples, each frozen primary tumor specimen had a
companion normal tissue specimen (blood or blood components, including
DNA extracted at the TSS). Adjacent nontumor tissue was also submitted
for a subset of cases (n = 20).
Cases were staged according to the American Joint Committee on Cancer
(AJCC) staging system. Pathology quality control was performed on each tu-
mor specimen and on adjacent normal tissue (where available) from a frozen2792 Cell Reports 18, 2780–2794, March 14, 2017section slide prepared either by the BCR or by the TSS. H&E-stained sec-
tions from each sample were made available on to a team of independent
pathologists for review to: confirm consistency with CCA histology, confirm
that the adjacent tissue specimen contained no tumor cells, and annotate
various standard pathological parameters. Only tumor samples with
R60% tumor nuclei, and %20% necrosis were submitted for nucleic acid
extraction.
The data and analysis results can be explored through the TCGA Data Portal
(https://gdc-portal.nci.nih.gov/projects/TCGA-CHOL), the Broad Institute
GDAC FireBrowse portal (http://firebrowse.org/?cohort=CHOL), and Memo-
rial Sloan Kettering Cancer Center cBioPortal (http://www.cbioportal.org/
study.do?cancer_study_id=chol_tcga#summary). Detailed experimental pro-
cedures are included in the Supplemental Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and nine tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2017.02.033.
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